PARP Inhibitors Market is expected to reach US$ 11.56 Bn. at a CAGR of 11.10% during the forecast period 2029.PARP Inhibitors Market Introduction and Overview
Cancer is the most devastating disease of our time. According to the World Health Organisation, it is the second most cause of death globally. The globally increasing prevalence of cancer has increased the demand for efficient drugs, targeted therapies, and precision medicines. Precision medicines have revolutionized cancer therapies by the concept of targeting selective cancer cells. Over the past decade Poly ADP-ribose Polymerases (PARP) have emerged as a new target in cancer therapy.To know about the Research Methodology :- Request Free Sample Report PARP inhibitors are a successful example of precision medicine, as the first drugs targeting specific cancer cells. They work by preventing cells from repairing their DNA which is damaged by the chemotherapy agents. Moreover, a combination of chemotherapy and PARP inhibitors can help in reducing the proliferation of cancer cells. Rising cancer cases, funding initiatives by governments, and advanced treatment techniques are elevating the PARP inhibitors market. Cancer Australia’s “Supporting people with Cancer” grant initiative provides organisation with grants up to $120,000 to support projects aimed at reducing the cancer burden. Effective partnerships between organisations to improve coordination, accessibility, and development of quality cancer support networks are also responsible for the market growth. Strict government regulations may restrain the market from growing.
PARP Inhibitors Market Segment Analysis
The drug type segment has dominated the Global PARP Inhibitors market. The increasing demand for drugs is boosting the market growth. Increased number of product approvals such as Lynparza (Olaprib), Niraparib, and Rucaparib by the FDA for ovarian cancer have elevated the market. Moreover, several other PARP Inhibitors that exhibit promising results are in the last stages of clinical trials. In the Indication segment, Ovarian cancer held a dominant position in 2022. PARP Inhibitors are extensively used in ovarian cancer treatments as they help repair damaged DNA.
PARP Inhibitors Market Regional Insights
North America holds a dominant position in the global PARP inhibitors market. Owing to the rising prevalence of the geriatric population and the large number of diseases and disorders, the region’s dominance is high. The rising elderly population is likely to drive the global PARP Inhibitors Market during the forecast period. Increasing research on BRCA-mutation tumours, ovarian cancer, and awareness about the disease is generating a revenue potential for the market in the APAC region. The objective of the report is to present a comprehensive analysis of the Global PARP Inhibitors Marketincluding all the stakeholders of the industry. The past and current status of the industry with forecasted market size and trends are presented in the report with the analysis of complicated data in simple language. The report covers all the aspects of the industry with a dedicated study of key players that includes market leaders, followers, and new entrants. PORTER, SVOR, PESTEL analysis with the potential impact of micro-economic factors of the market have been presented in the report. External as well as internal factors that are supposed to affect the business positively or negatively have been analysed, which will give a clear futuristic view of the industry to the decision-makers. The report also helps in understanding Global PARP Inhibitors Marketdynamics, structure by analyzing the market segments and project the Global PARP Inhibitors Marketsize. Clear representation of competitive analysis of key players by product, price, financial position, product portfolio, growth strategies, and regional presence in Global PARP Inhibitors Marketmake the report investor’s guide.PARP Inhibitors Market Scope: Inquire before buying
Global PARP Inhibitors Market Report Coverage Details Base Year: 2022 Forecast Period: 2023-2029 Historical Data: 2018 to 2022 Market Size in 2022: US$ 5.53 Bn. Forecast Period 2023 to 2029 CAGR: 11.10% Market Size in 2029: US$ 11.56 Bn. Segments Covered: by Drug-type Lynparza Niraparib Rucaparib Talazoparib Veliparib by Indication Ovarian Cancer Breast Cancer Prostate Cancer Pancreatic Cancer by Distribution Channels Hospital Pharmacies Retail Pharmacies Online Pharmacies PARP Inhibitors Market, by Region
North America (United States, Canada and Mexico) Europe (UK, France, Germany, Italy, Spain, Sweden, Austria and Rest of Europe) Asia Pacific (China, South Korea, Japan, India, Australia, Indonesia, Malaysia, Vietnam, Taiwan, Bangladesh, Pakistan and Rest of APAC) Middle East and Africa (South Africa, GCC, Egypt, Nigeria and Rest of ME&A) South America (Brazil, Argentina Rest of South America)PARP Inhibitors Market Key Players
1. AstraZeneca 2. Tesaro 3. AbbVie Inc 4. Medivation 5. Clovis Oncology 6. Johnson & Johnson 7. GlaxoSmithKline plc 8. Pfizer Inc 9. Bristol-Myers Squibb 10.Merck KGaA 11.Genentech Inc 12.Repare Therapeutics 13.Sierra Oncology 14.Karyopharm Therapeutics Inc 15.Ono Pharmaceutical Co. Ltd Frequently Asked Questions: 1. Which region has the largest share in Global Parp Inhibitors Market? Ans: North America region held the highest share in 2022. 2. What is the growth rate of Global Parp Inhibitors Market? Ans: The Global Parp Inhibitors Market is expected to growing at a CAGR of 11.10% during forecast period 2023-2029. 3. What is scope of the Global Parp Inhibitors market report? Ans: Global Parp Inhibitors Market report helps with the PESTEL, PORTER, COVID-19 Impact analysis, Recommendations for Investors & Leaders, and market estimation of the forecast period. 4. Who are the key players in Global Parp Inhibitors market? Ans: The important key players in the Global Parp Inhibitors Market are AstraZeneca, Tesaro, AbbVie Inc, Medivation, Clovis Oncology, Johnson & Johnson, GlaxoSmithKline plc, Pfizer Inc, Bristol-Myers Squibb, Merck KGaA, Genentech Inc, Repare Therapeutics, Sierra Oncology, Karyopharm Therapeutics Inc, and Ono Pharmaceutical Co. Ltd. 5. What is the study period of this market? Ans: The Global Parp Inhibitors Market is studied from 2022 to 2029.
Global PARP Inhibitors Market 1. Preface 1.1. Report Scope and Market Segmentation 1.2. Research Highlights 1.3. Research Objectives 2. Assumptions and Research Methodology 2.1. Report Assumptions 2.2. Abbreviations 2.3. Research Methodology 2.3.1. Secondary Research 2.3.1.1. Secondary data 2.3.1.2. Secondary Sources 2.3.2. Primary Research 2.3.2.1. Data from Primary Sources 2.3.2.2. Breakdown of Primary Sources 3. Executive Summary: PARP Inhibitors MarketSize, By Market Value (US$ Mn) 4. Market Overview 4.1. Introduction 4.2. Market Indicator 4.2.1. Drivers 4.2.2. Restraints 4.2.3. Opportunities 4.2.4. Challenges 4.3. Porter’s Analysis 4.4. Value Chain Analysis 4.5. Market Risk Analysis 4.6. SWOT Analysis 4.7. Industry Trends and Emerging Technologies 5. Supply Side and Demand Side Indicators 6. Global PARP Inhibitors MarketAnalysis and Forecast 6.1. PARP Inhibitors MarketSize & Y-o-Y Growth Analysis 6.1.1. North America 6.1.2. Europe 6.1.3. Asia Pacific 6.1.4. Middle East & Africa 6.1.5. South America 7. Global PARP Inhibitors MarketAnalysis and Forecast, By Drug-type 7.1. Introduction and Definition 7.2. Key Findings 7.3. PARP Inhibitors MarketValue Share Analysis, By Drug-type 7.4. PARP Inhibitors MarketSize (US$ Mn) Forecast, By Drug-type 7.5. PARP Inhibitors MarketAnalysis, By Drug-type 7.6. PARP Inhibitors MarketAttractiveness Analysis, By Drug-type 8. Global PARP Inhibitors MarketAnalysis and Forecast, By Indication 8.1. Introduction and Definition 8.2. Key Findings 8.3. PARP Inhibitors MarketValue Share Analysis, By Indication 8.4. PARP Inhibitors MarketSize (US$ Mn) Forecast, By Indication 8.5. PARP Inhibitors MarketAnalysis, By Indication 8.6. PARP Inhibitors MarketAttractiveness Analysis, By Indication 9. Global PARP Inhibitors MarketAnalysis and Forecast By Distribution Channels 9.1. Introduction and Definition 9.2. Key Findings 9.3. PARP Inhibitors MarketValue Share Analysis, By Distribution Channels 9.4. PARP Inhibitors MarketSize (US$ Mn) Forecast, By Distribution Channels 9.5. PARP Inhibitors MarketAnalysis, By Distribution Channels 9.6. PARP Inhibitors MarketAttractiveness Analysis, By Distribution Channels 10. Global PARP Inhibitors MarketAnalysis, By Region 10.1. PARP Inhibitors MarketValue Share Analysis, By Region 10.2. PARP Inhibitors MarketSize (US$ Mn) Forecast, By Region 10.3. PARP Inhibitors MarketAttractiveness Analysis, By Region 11. North America PARP Inhibitors MarketAnalysis 11.1. Key Findings 11.2. North America PARP Inhibitors MarketOverview 11.3. North America PARP Inhibitors MarketValue Share Analysis, By Drug-type 11.4. North America PARP Inhibitors MarketForecast, By Drug-type 11.4.1. Lynparza 11.4.2. Niraparib 11.4.3. Rucaparib 11.4.4. Talazoparib 11.4.5. Veliparib 11.5. North America PARP Inhibitors MarketValue Share Analysis, By Indication 11.6. North America PARP Inhibitors MarketForecast, By Indication 11.6.1. Ovarian Cancer 11.6.2. Breast Cancer 11.6.3. Prostate Cancer 11.6.4. Pancreatic Cancer 11.7. North America PARP Inhibitors MarketValue Share Analysis, By Distribution Channels 11.8. North America PARP Inhibitors MarketForecast, By Distribution Channels 11.8.1. Hospital Pharmacies 11.8.2. Retail Pharmacies 11.8.3. Online Pharmacies 11.9. North America PARP Inhibitors MarketValue Share Analysis, By Country 11.10. North America PARP Inhibitors MarketForecast, By Country 11.10.1. U.S. 11.10.2. Canada 11.10.3. Mexico 11.11. North America PARP Inhibitors MarketAnalysis, By Country 11.12. U.S. PARP Inhibitors MarketForecast, By Drug-type 11.12.1. Lynparza 11.12.2. Niraparib 11.12.3. Rucaparib 11.12.4. Talazoparib 11.12.5. Veliparib 11.13. U.S. PARP Inhibitors MarketForecast, By Indication 11.13.1. Ovarian Cancer 11.13.2. Breast Cancer 11.13.3. Prostate Cancer 11.13.4. Pancreatic Cancer 11.14. U.S. PARP Inhibitors MarketForecast, By Distribution Channels 11.14.1. Hospital Pharmacies 11.14.2. Retail Pharmacies 11.14.3. Online Pharmacies 11.15. Canada PARP Inhibitors MarketForecast, By Drug-type 11.15.1. Lynparza 11.15.2. Niraparib 11.15.3. Rucaparib 11.15.4. Talazoparib 11.15.5. Veliparib 11.16. Canada PARP Inhibitors MarketForecast, By Indication 11.16.1. Ovarian Cancer 11.16.2. Breast Cancer 11.16.3. Prostate Cancer 11.16.4. Pancreatic Cancer 11.17. Canada PARP Inhibitors MarketForecast, By Distribution Channels 11.17.1. Hospital Pharmacies 11.17.2. Retail Pharmacies 11.17.3. Online Pharmacies 11.18. Mexico PARP Inhibitors MarketForecast, By Drug-type 11.18.1. Lynparza 11.18.2. Niraparib 11.18.3. Rucaparib 11.18.4. Talazoparib 11.18.5. Veliparib 11.19. Mexico PARP Inhibitors MarketForecast, By Indication 11.19.1. Ovarian Cancer 11.19.2. Breast Cancer 11.19.3. Prostate Cancer 11.19.4. Pancreatic Cancer 11.20. Mexico PARP Inhibitors MarketForecast, By Distribution Channels 11.20.1. Hospital Pharmacies 11.20.2. Retail Pharmacies 11.20.3. Online Pharmacies 11.21. North America PARP Inhibitors MarketAttractiveness Analysis 11.21.1. By Drug-type 11.21.2. By Indication 11.21.3. By Distribution Channels 11.22. PEST Analysis 11.23. Key Trends 11.24. Key Developments 12. Europe PARP Inhibitors MarketAnalysis 12.1. Key Findings 12.2. Europe PARP Inhibitors MarketOverview 12.3. Europe PARP Inhibitors MarketValue Share Analysis, By Drug-type 12.4. Europe PARP Inhibitors MarketForecast, By Drug-type 12.4.1. Lynparza 12.4.2. Niraparib 12.4.3. Rucaparib 12.4.4. Talazoparib 12.4.5. Veliparib 12.5. Europe PARP Inhibitors MarketValue Share Analysis, By Indication 12.6. Europe PARP Inhibitors MarketForecast, By Indication 12.6.1. Ovarian Cancer 12.6.2. Breast Cancer 12.6.3. Prostate Cancer 12.6.4. Pancreatic Cancer 12.7. Europe PARP Inhibitors MarketValue Share Analysis, By Distribution Channels 12.8. Europe PARP Inhibitors MarketForecast, By Distribution Channels 12.8.1. Hospital Pharmacies 12.8.2. Retail Pharmacies 12.8.3. Online Pharmacies 12.9. Europe PARP Inhibitors MarketValue Share Analysis, By Country 12.10. Europe PARP Inhibitors MarketForecast, By Country 12.10.1. Germany 12.10.2. U.K. 12.10.3. France 12.10.4. Italy 12.10.5. Spain 12.10.6. Sweden 12.10.7. CIS countries 12.10.8. Rest of Europe 12.11. Germany PARP Inhibitors MarketForecast, By Drug-type 12.11.1. Lynparza 12.11.2. Niraparib 12.11.3. Rucaparib 12.11.4. Talazoparib 12.11.5. Veliparib 12.12. Germany PARP Inhibitors MarketForecast, By Indication 12.12.1. Ovarian Cancer 12.12.2. Breast Cancer 12.12.3. Prostate Cancer 12.12.4. Pancreatic Cancer 12.13. Germany PARP Inhibitors MarketForecast, By Distribution Channels 12.13.1. Hospital Pharmacies 12.13.2. Retail Pharmacies 12.13.3. Online Pharmacies 12.14. U.K. PARP Inhibitors MarketForecast, By Drug-type 12.14.1. Lynparza 12.14.2. Niraparib 12.14.3. Rucaparib 12.14.4. Talazoparib 12.14.5. Veliparib 12.15. U.K. PARP Inhibitors MarketForecast, By Indication 12.15.1. Ovarian Cancer 12.15.2. Breast Cancer 12.15.3. Prostate Cancer 12.15.4. Pancreatic Cancer 12.16. U.K. PARP Inhibitors MarketForecast, By Distribution Channels 12.16.1. Hospital Pharmacies 12.16.2. Retail Pharmacies 12.16.3. Online Pharmacies 12.17. France PARP Inhibitors MarketForecast, By Drug-type 12.17.1. Lynparza 12.17.2. Niraparib 12.17.3. Rucaparib 12.17.4. Talazoparib 12.17.5. Veliparib 12.18. France PARP Inhibitors MarketForecast, By Indication 12.18.1. Ovarian Cancer 12.18.2. Breast Cancer 12.18.3. Prostate Cancer 12.18.4. Pancreatic Cancer 12.19. France PARP Inhibitors MarketForecast, By Distribution Channels 12.19.1. Hospital Pharmacies 12.19.2. Retail Pharmacies 12.19.3. Online Pharmacies 12.20. Italy PARP Inhibitors MarketForecast, By Drug-type 12.20.1. Lynparza 12.20.2. Niraparib 12.20.3. Rucaparib 12.20.4. Talazoparib 12.20.5. Veliparib 12.21. Italy PARP Inhibitors MarketForecast, By Indication 12.21.1. Ovarian Cancer 12.21.2. Breast Cancer 12.21.3. Prostate Cancer 12.21.4. Pancreatic Cancer 12.22. Italy PARP Inhibitors MarketForecast, By Distribution Channels 12.22.1. Hospital Pharmacies 12.22.2. Retail Pharmacies 12.22.3. Online Pharmacies 12.23. Spain PARP Inhibitors MarketForecast, By Drug-type 12.23.1. Lynparza 12.23.2. Niraparib 12.23.3. Rucaparib 12.23.4. Talazoparib 12.23.5. Veliparib 12.24. Spain PARP Inhibitors MarketForecast, By Indication 12.24.1. Ovarian Cancer 12.24.2. Breast Cancer 12.24.3. Prostate Cancer 12.24.4. Pancreatic Cancer 12.25. Spain PARP Inhibitors MarketForecast, By Distribution Channels 12.25.1. Hospital Pharmacies 12.25.2. Retail Pharmacies 12.25.3. Online Pharmacies 12.26. Sweden PARP Inhibitors MarketForecast, By Drug-type 12.26.1. Lynparza 12.26.2. Niraparib 12.26.3. Rucaparib 12.26.4. Talazoparib 12.26.5. Veliparib 12.27. Sweden PARP Inhibitors MarketForecast, By Indication 12.27.1. Ovarian Cancer 12.27.2. Breast Cancer 12.27.3. Prostate Cancer 12.27.4. Pancreatic Cancer 12.28. Sweden PARP Inhibitors MarketForecast, By Distribution Channels 12.28.1. Hospital Pharmacies 12.28.2. Retail Pharmacies 12.28.3. Online Pharmacies 12.29. CIS countries PARP Inhibitors MarketForecast, By Drug-type 12.29.1. Lynparza 12.29.2. Niraparib 12.29.3. Rucaparib 12.29.4. Talazoparib 12.29.5. Veliparib 12.30. CIS countries PARP Inhibitors MarketForecast, By Indication 12.30.1. Ovarian Cancer 12.30.2. Breast Cancer 12.30.3. Prostate Cancer 12.30.4. Pancreatic Cancer 12.31. CIS countries PARP Inhibitors MarketForecast, By Distribution Channels 12.31.1. Hospital Pharmacies 12.31.2. Retail Pharmacies 12.31.3. Online Pharmacies 12.32. Rest of Europe PARP Inhibitors MarketForecast, By Drug-type 12.32.1. Lynparza 12.32.2. Niraparib 12.32.3. Rucaparib 12.32.4. Talazoparib 12.32.5. Veliparib 12.33. Rest of Europe PARP Inhibitors MarketForecast, By Indication 12.33.1. Ovarian Cancer 12.33.2. Breast Cancer 12.33.3. Prostate Cancer 12.33.4. Pancreatic Cancer 12.34. Rest of Europe PARP Inhibitors MarketForecast, By Distribution Channels 12.34.1. Hospital Pharmacies 12.34.2. Retail Pharmacies 12.34.3. Online Pharmacies 12.35. Europe PARP Inhibitors MarketAttractiveness Analysis 12.35.1. By Indication 12.35.2. By Drug-type 12.35.3. By Distribution Channels 12.36. PEST Analysis 12.37. Key Trends 12.38. Key Developments 13. Asia Pacific PARP Inhibitors MarketAnalysis 13.1. Key Findings 13.2. Asia Pacific PARP Inhibitors MarketOverview 13.3. Asia Pacific PARP Inhibitors MarketValue Share Analysis, By Drug-type 13.4. Asia Pacific PARP Inhibitors MarketForecast, By Drug-type 13.4.1. Lynparza 13.4.2. Niraparib 13.4.3. Rucaparib 13.4.4. Talazoparib 13.4.5. Veliparib 13.5. Asia Pacific PARP Inhibitors MarketValue Share Analysis, By Indication 13.6. Asia Pacific PARP Inhibitors MarketForecast, By Indication 13.6.1. Ovarian Cancer 13.6.2. Breast Cancer 13.6.3. Prostate Cancer 13.6.4. Pancreatic Cancer 13.7. Asia Pacific PARP Inhibitors MarketValue Share Analysis, By Distribution Channels 13.8. Asia Pacific PARP Inhibitors MarketForecast, By Distribution Channels 13.8.1. Hospital Pharmacies 13.8.2. Retail Pharmacies 13.8.3. Online Pharmacies 13.9. Asia Pacific PARP Inhibitors MarketValue Share Analysis, By Country 13.10. Asia Pacific PARP Inhibitors MarketForecast, By Country 13.10.1. China 13.10.2. India 13.10.3. Japan 13.10.4. South Korea 13.10.5. Australia 13.10.6. ASEAN 13.10.7. Rest of Asia Pacific 13.11. Asia Pacific PARP Inhibitors MarketAnalysis, By Country 13.12. China PARP Inhibitors MarketForecast, By Drug-type 13.12.1. Lynparza 13.12.2. Niraparib 13.12.3. Rucaparib 13.12.4. Talazoparib 13.12.5. Veliparib 13.13. China PARP Inhibitors MarketForecast, By Indication 13.13.1. Ovarian Cancer 13.13.2. Breast Cancer 13.13.3. Prostate Cancer 13.13.4. Pancreatic Cancer 13.14. China PARP Inhibitors MarketForecast, By Distribution Channels 13.14.1. Hospital Pharmacies 13.14.2. Retail Pharmacies 13.14.3. Online Pharmacies 13.15. India PARP Inhibitors MarketForecast, By Drug-type 13.15.1. Lynparza 13.15.2. Niraparib 13.15.3. Rucaparib 13.15.4. Talazoparib 13.15.5. Veliparib 13.16. India PARP Inhibitors MarketForecast, By Indication 13.16.1. Ovarian Cancer 13.16.2. Breast Cancer 13.16.3. Prostate Cancer 13.16.4. Pancreatic Cancer 13.17. India PARP Inhibitors MarketForecast, By Distribution Channels 13.17.1. Hospital Pharmacies 13.17.2. Retail Pharmacies 13.17.3. Online Pharmacies 13.18. Japan PARP Inhibitors MarketForecast, By Drug-type 13.18.1. Lynparza 13.18.2. Niraparib 13.18.3. Rucaparib 13.18.4. Talazoparib 13.18.5. Veliparib 13.19. Japan PARP Inhibitors MarketForecast, By Indication 13.19.1. Ovarian Cancer 13.19.2. Breast Cancer 13.19.3. Prostate Cancer 13.19.4. Pancreatic Cancer 13.20. Japan PARP Inhibitors MarketForecast, By Distribution Channels 13.20.1. Hospital Pharmacies 13.20.2. Retail Pharmacies 13.20.3. Online Pharmacies 13.21. South Korea PARP Inhibitors MarketForecast, By Drug-type 13.21.1. Lynparza 13.21.2. Niraparib 13.21.3. Rucaparib 13.21.4. Talazoparib 13.21.5. Veliparib 13.22. South Korea PARP Inhibitors MarketForecast, By Indication 13.22.1. Ovarian Cancer 13.22.2. Breast Cancer 13.22.3. Prostate Cancer 13.22.4. Pancreatic Cancer 13.23. South Korea PARP Inhibitors MarketForecast, By Distribution Channels 13.23.1. Hospital Pharmacies 13.23.2. Retail Pharmacies 13.23.3. Online Pharmacies 13.24. Australia PARP Inhibitors MarketForecast, By Drug-type 13.24.1. Lynparza 13.24.2. Niraparib 13.24.3. Rucaparib 13.24.4. Talazoparib 13.24.5. Veliparib 13.25. Australia PARP Inhibitors MarketForecast, By Indication 13.25.1. Ovarian Cancer 13.25.2. Breast Cancer 13.25.3. Prostate Cancer 13.25.4. Pancreatic Cancer 13.26. Australia PARP Inhibitors MarketForecast, By Distribution Channels 13.26.1. Hospital Pharmacies 13.26.2. Retail Pharmacies 13.26.3. Online Pharmacies 13.27. ASEAN PARP Inhibitors MarketForecast, By Drug-type 13.27.1. Lynparza 13.27.2. Niraparib 13.27.3. Rucaparib 13.27.4. Talazoparib 13.27.5. Veliparib 13.28. ASEAN PARP Inhibitors MarketForecast, By Indication 13.28.1. Ovarian Cancer 13.28.2. Breast Cancer 13.28.3. Prostate Cancer 13.28.4. Pancreatic Cancer 13.29. ASEAN PARP Inhibitors MarketForecast, By Distribution Channels 13.29.1. Hospital Pharmacies 13.29.2. Retail Pharmacies 13.29.3. Online Pharmacies 13.30. Rest of Asia Pacific PARP Inhibitors MarketForecast, By Drug-type 13.30.1. Lynparza 13.30.2. Niraparib 13.30.3. Rucaparib 13.30.4. Talazoparib 13.30.5. Veliparib 13.31. Rest of Asia Pacific PARP Inhibitors MarketForecast, By Indication 13.31.1. Ovarian Cancer 13.31.2. Breast Cancer 13.31.3. Prostate Cancer 13.31.4. Pancreatic Cancer 13.32. Rest of Asia Pacific PARP Inhibitors MarketForecast, By Distribution Channels 13.32.1. Hospital Pharmacies 13.32.2. Retail Pharmacies 13.32.3. Online Pharmacies 13.33. Asia Pacific PARP Inhibitors MarketAttractiveness Analysis 13.33.1. By Drug-type 13.33.2. By Indication 13.33.3. By Distribution Channels 13.34. PEST Analysis 13.35. Key Trends 13.36. Key Developments 14. Middle East & Africa PARP Inhibitors MarketAnalysis 14.1. Key Findings 14.2. Middle East & Africa PARP Inhibitors MarketOverview 14.3. Middle East & Africa PARP Inhibitors MarketValue Share Analysis, By Drug-type 14.4. Middle East & Africa PARP Inhibitors MarketForecast, By Drug-type 14.4.1. Lynparza 14.4.2. Niraparib 14.4.3. Rucaparib 14.4.4. Talazoparib 14.4.5. Veliparib 14.5. Middle East & Africa PARP Inhibitors MarketValue Share Analysis, By Indication 14.6. Middle East & Africa PARP Inhibitors MarketForecast, By Indication 14.6.1. Ovarian Cancer 14.6.2. Breast Cancer 14.6.3. Prostate Cancer 14.6.4. Pancreatic Cancer 14.7. Middle East & Africa PARP Inhibitors MarketValue Share Analysis, By Distribution Channels 14.8. Middle East & Africa PARP Inhibitors MarketForecast, By Distribution Channels 14.8.1. Hospital Pharmacies 14.8.2. Retail Pharmacies 14.8.3. Online Pharmacies 14.9. Middle East & Africa PARP Inhibitors MarketValue Share Analysis, By Country 14.10. Middle East & Africa PARP Inhibitors MarketForecast, By Country 14.10.1. GCC Countries 14.10.2. South Africa 14.10.3. Nigeria 14.10.4. Egypt 14.10.5. Rest of Middle East & Africa 14.11. Middle East & Africa PARP Inhibitors MarketAnalysis, By Country 14.12. GCC Countries PARP Inhibitors MarketForecast, By Drug-type 14.12.1. Lynparza 14.12.2. Niraparib 14.12.3. Rucaparib 14.12.4. Talazoparib 14.12.5. Veliparib 14.13. GCC Countries PARP Inhibitors MarketForecast, By Indication 14.13.1. Ovarian Cancer 14.13.2. Breast Cancer 14.13.3. Prostate Cancer 14.13.4. Pancreatic Cancer 14.14. GCC Countries PARP Inhibitors MarketForecast, By Distribution Channels 14.14.1. Hospital Pharmacies 14.14.2. Retail Pharmacies 14.14.3. Online Pharmacies 14.15. South Africa PARP Inhibitors MarketForecast, By Drug-type 14.15.1. Lynparza 14.15.2. Niraparib 14.15.3. Rucaparib 14.15.4. Talazoparib 14.15.5. Veliparib 14.16. South Africa PARP Inhibitors MarketForecast, By Indication 14.16.1. Ovarian Cancer 14.16.2. Breast Cancer 14.16.3. Prostate Cancer 14.16.4. Pancreatic Cancer 14.17. South Africa PARP Inhibitors MarketForecast, By Distribution Channels 14.17.1. Hospital Pharmacies 14.17.2. Retail Pharmacies 14.17.3. Online Pharmacies 14.18. Nigeria PARP Inhibitors MarketForecast, By Drug-type 14.18.1. Lynparza 14.18.2. Niraparib 14.18.3. Rucaparib 14.18.4. Talazoparib 14.18.5. Veliparib 14.19. Nigeria PARP Inhibitors MarketForecast, By Indication 14.19.1. Ovarian Cancer 14.19.2. Breast Cancer 14.19.3. Prostate Cancer 14.19.4. Pancreatic Cancer 14.20. Nigeria PARP Inhibitors MarketForecast, By Distribution Channels 14.20.1. Hospital Pharmacies 14.20.2. Retail Pharmacies 14.20.3. Online Pharmacies 14.21. Egypt PARP Inhibitors MarketForecast, By Drug-type 14.21.1. Lynparza 14.21.2. Niraparib 14.21.3. Rucaparib 14.21.4. Talazoparib 14.21.5. Veliparib 14.22. Egypt PARP Inhibitors MarketForecast, By Indication 14.22.1. Ovarian Cancer 14.22.2. Breast Cancer 14.22.3. Prostate Cancer 14.22.4. Pancreatic Cancer 14.23. Egypt PARP Inhibitors MarketForecast, By Distribution Channels 14.23.1. Hospital Pharmacies 14.23.2. Retail Pharmacies 14.23.3. Online Pharmacies 14.24. Rest of Middle East & Africa PARP Inhibitors MarketForecast, By Drug-type 14.24.1. Lynparza 14.24.2. Niraparib 14.24.3. Rucaparib 14.24.4. Talazoparib 14.24.5. Veliparib 14.25. Rest of Middle East & Africa PARP Inhibitors MarketForecast, By Indication 14.25.1. Ovarian Cancer 14.25.2. Breast Cancer 14.25.3. Prostate Cancer 14.25.4. Pancreatic Cancer 14.26. Rest of Middle East & Africa PARP Inhibitors MarketForecast, By Distribution Channels 14.26.1. Hospital Pharmacies 14.26.2. Retail Pharmacies 14.26.3. Online Pharmacies 14.27. Middle East & Africa PARP Inhibitors MarketAttractiveness Analysis 14.27.1. By Drug-type 14.27.2. By Indication 14.27.3. By Distribution Channels 14.28. PEST Analysis 14.29. Key Trends 14.30. Key Developments 15. South America PARP Inhibitors MarketAnalysis 15.1. Key Findings 15.2. South America PARP Inhibitors MarketOverview 15.3. South America PARP Inhibitors MarketValue Share Analysis, By Drug-type 15.4. South America PARP Inhibitors MarketForecast, By Drug-type 15.4.1. Lynparza 15.4.2. Niraparib 15.4.3. Rucaparib 15.4.4. Talazoparib 15.4.5. Veliparib 15.5. South America PARP Inhibitors MarketValue Share Analysis, By Indication 15.6. South America PARP Inhibitors MarketForecast, By Indication 15.6.1. Ovarian Cancer 15.6.2. Breast Cancer 15.6.3. Prostate Cancer 15.6.4. Pancreatic Cancer 15.7. South America PARP Inhibitors MarketValue Share Analysis, By Distribution Channels 15.8. South America PARP Inhibitors MarketForecast, By Distribution Channels 15.8.1. Hospital Pharmacies 15.8.2. Retail Pharmacies 15.8.3. Online Pharmacies 15.9. South America PARP Inhibitors MarketValue Share Analysis, By Country 15.10. South America PARP Inhibitors MarketForecast, By Country 15.10.1. Brazil 15.10.2. Colombia 15.10.3. Argentina 15.10.4. Rest of South America 15.11. South America PARP Inhibitors MarketAnalysis, By Country 15.12. Brazil PARP Inhibitors MarketForecast, By Drug-type 15.12.1. Lynparza 15.12.2. Niraparib 15.12.3. Rucaparib 15.12.4. Talazoparib 15.12.5. Veliparib 15.13. Brazil PARP Inhibitors MarketForecast, By Indication 15.13.1. Ovarian Cancer 15.13.2. Breast Cancer 15.13.3. Prostate Cancer 15.13.4. Pancreatic Cancer 15.14. Brazil PARP Inhibitors MarketForecast, By Distribution Channels 15.14.1. Hospital Pharmacies 15.14.2. Retail Pharmacies 15.14.3. Online Pharmacies 15.15. Colombia PARP Inhibitors MarketForecast, By Drug-type 15.15.1. Lynparza 15.15.2. Niraparib 15.15.3. Rucaparib 15.15.4. Talazoparib 15.15.5. Veliparib 15.16. Colombia PARP Inhibitors MarketForecast, By Indication 15.16.1. Ovarian Cancer 15.16.2. Breast Cancer 15.16.3. Prostate Cancer 15.16.4. Pancreatic Cancer 15.17. Colombia PARP Inhibitors MarketForecast, By Distribution Channels 15.17.1. Hospital Pharmacies 15.17.2. Retail Pharmacies 15.17.3. Online Pharmacies 15.18. Argentina PARP Inhibitors MarketForecast, By Drug-type 15.18.1. Lynparza 15.18.2. Niraparib 15.18.3. Rucaparib 15.18.4. Talazoparib 15.18.5. Veliparib 15.19. Argentina PARP Inhibitors MarketForecast, By Indication 15.19.1. Ovarian Cancer 15.19.2. Breast Cancer 15.19.3. Prostate Cancer 15.19.4. Pancreatic Cancer 15.20. Argentina PARP Inhibitors MarketForecast, By Distribution Channels 15.20.1. Hospital Pharmacies 15.20.2. Retail Pharmacies 15.20.3. Online Pharmacies 15.21. Rest of South America PARP Inhibitors MarketForecast, By Drug-type 15.21.1. Lynparza 15.21.2. Niraparib 15.21.3. Rucaparib 15.21.4. Talazoparib 15.21.5. Veliparib 15.22. Rest of South America PARP Inhibitors MarketForecast, By Indication 15.22.1. Ovarian Cancer 15.22.2. Breast Cancer 15.22.3. Prostate Cancer 15.22.4. Pancreatic Cancer 15.23. Rest of South America PARP Inhibitors MarketForecast, By Distribution Channels 15.23.1. Hospital Pharmacies 15.23.2. Retail Pharmacies 15.23.3. Online Pharmacies 15.24. South America PARP Inhibitors MarketAttractiveness Analysis 15.24.1. By Drug-type 15.24.2. By Indication 15.24.3. By Distribution Channels 15.25. PEST Analysis 15.26. Key Trends 15.27. Key Developments 16. Company Profiles 16.1. Market Share Analysis, By Company 16.2. Competition Matrix 16.2.1. Competitive Benchmarking of key players By price, presence, market share, Indication, and R&D investment 16.2.2. New Product Launches and Product Enhancements 16.2.3. Market Consolidation 16.2.3.1. M&A By Regions, Investment and Indication 16.2.3.2. M&A Key Players, Forward Integration and Backward Integration 16.3. Company Profiles: Key Players 16.3.1. AstraZeneca 16.3.1.1. Company Overview 16.3.1.2. Financial Overview 16.3.1.3. Product Portfolio 16.3.1.4. Business Strategy 16.3.1.5. Recent Developments 16.3.1.6. Development Footprint 16.3.2. Tesaro 16.3.3. AbbVie Inc 16.3.4. Medivation 16.3.5. Clovis Oncology 16.3.6. Johnson & Johnson 16.3.7. GlaxoSmithKline plc 16.3.8. Pfizer Inc 16.3.9. Bristol-Myers Squibb 16.3.10. Merck KGaA 16.3.11. Genentech Inc 16.3.12. Repare Therapeutics 16.3.13. Sierra Oncology 16.3.14. Karyopharm Therapeutics Inc 16.3.15. Ono Pharmaceutical Co. Ltd